Universe Pharmaceuticals INC announced on Nov. 1, 2024, that it received a notification from Nasdaq on Oct. 25, 2024, regarding non-compliance with the minimum bid price requirement. The company's ordinary shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days from Sep. 13 to Oct. 24, 2024.The company has been granted 180 calendar days, until Apr. 23, 2025, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for additional time or face potential delisting. Universe Pharmaceuticals stated that its business operations are unaffected and it will monitor the situation, considering options such as a reverse share split if appropriate.Universe Pharmaceuticals, based in Ji'an, Jiangxi, China, specializes in manufacturing and distributing traditional Chinese medicine derivatives for the elderly, as well as biomedical drugs and dietary supplements. The company's products are currently sold in 30 Chinese provinces.

Universe Pharmaceuticals INC announced on Nov. 1, 2024, that it received a notification from Nasdaq on Oct. 25, 2024, regarding non-compliance with the minimum bid price requirement. The company's ordinary shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days from Sep. 13 to Oct. 24, 2024.The company has been granted 180 calendar days, until Apr. 23, 2025, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for additional time or face potential delisting. Universe Pharmaceuticals stated that its business operations are unaffected and it will monitor the situation, considering options such as a reverse share split if appropriate.Universe Pharmaceuticals, based in Ji'an, Jiangxi, China, specializes in manufacturing and distributing traditional Chinese medicine derivatives for the elderly, as well as biomedical drugs and dietary supplements. The company's products are currently sold in 30 Chinese provinces.